Heat shock protein antagonists in early stage clinical trials for NSCLC

Lizza E. L. Hendriks, Anne-Marie C. Dingemans*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)541-550
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number5
DOIs
Publication statusPublished - May 2017

Keywords

  • Early clinical trials
  • Hsp90 inhibitors
  • Hsp27 inhibitors
  • Hsp70 inhibitors
  • non-small cell lung cancer
  • CELL LUNG-CANCER
  • HSP90 INHIBITOR GANETESPIB
  • ADVANCED SOLID TUMORS
  • I DOSE-ESCALATION
  • TYROSINE KINASE INHIBITORS
  • POTENT ANTITUMOR-ACTIVITY
  • GROWTH-FACTOR RECEPTOR
  • PHASE-I
  • ACQUIRED-RESISTANCE
  • OCULAR TOXICITY

Cite this